Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1.
Chenyin WangAlexandra HamacherPatrick PetzschKarl KöhrerGuenter NiegischMichèle Janine HoffmannWolfgang A SchulzMatthias Ulrich KassackPublished in: Cancers (2020)
Occurrence of cisplatin-resistance in bladder cancer is frequent and results in disease progression. Thus, novel therapeutic approaches are a high medical need for patients suffering from chemotherapy failure. The purpose of this study was to test the combination of the DNA methyltransferase inhibitor decitabine (DAC) with the histone deacetylase inhibitor entinostat (ENT) in bladder cancer cells with different platinum sensitivities: J82, cisplatin-resistant J82CisR, and RT-112. Intermittent treatment of J82 cells with cisplatin resulted in the six-fold more cisplatin-resistant cell line J82CisR. Combinations of DAC and/or ENT plus cisplatin could not reverse chemoresistance. However, the combination of DAC and ENT acted cytotoxic in a highly synergistic manner as shown by Chou-Talalay analysis via induction of apoptosis and cell cycle arrest. Importantly, this effect was cancer cell-selective as no synergism was found for the combination in the non-cancerous urothelial cell line HBLAK. Expression analysis indicated that epigenetic treatment led to up-regulation of forkhead box class O1 (FoxO1) and further activated proapoptotic Bim and the cell cycle regulator p21 and reduced expression of survivin in J82CisR. In conclusion, the combination of DAC and ENT is highly synergistic and has a promising potential for therapy of bladder cancer, particularly in cases with platinum resistance.
Keyphrases
- cell cycle arrest
- pi k akt
- cell cycle
- cell death
- transcription factor
- histone deacetylase
- end stage renal disease
- cell proliferation
- acute myeloid leukemia
- signaling pathway
- chronic kidney disease
- urinary tract
- induced apoptosis
- newly diagnosed
- gene expression
- ejection fraction
- poor prognosis
- oxidative stress
- risk assessment
- dna methylation
- squamous cell carcinoma
- binding protein
- drug delivery
- cell free
- cell therapy